Ngā hua rapu kaituhi :: APM

1

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME<sup>®</sup> trial mā Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka‐Weber

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories mā Adeera Levin, Vlado Perkovic, David C. Wheeler, Stefan Hantel, Jyothis T. George, Maximilian von Eynatten, Audrey Koitka‐Weber, Christoph Wanner

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial mā Odette S. Reifsnider, M. Feldman, Christoph Wanner, Egon Pfarr, Audrey Koitka‐Weber, Sarah Brand, Matthew Stargardter, Cheng Wang, Effie Kuti, Anastasia Ustyugova

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective o... mā Gert Mayer, Christoph Wanner, Matthew R. Weir, Silvio E. Inzucchi, Audrey Koitka‐Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z.I. Cherney

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure mā Javed Butler, Faı̈ez Zannad, David Fitchett, Bernard Zinman, Audrey Koitka‐Weber, Maximilian von Eynatten, Isabella Zwiener, Jyothis T. George, Martina Brueckmann, Alfred K. Cheung, Christoph Wanner

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial mā Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J.L. Heerspink

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function mā Erik J.M. van Bommel, Yuliya Lytvyn, Bruce A. Perkins, Nima Soleymanlou, Nora Fagan, Audrey Koitka‐Weber, Jaap A. Joles, David Z.I. Cherney, Daniël H. van Raalte

I whakaputaina 2020

Whiwhi kuputuhi katoa
Editorial

Tiaki ki tētahi rārangi

I tiakina i:
8

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial mā Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Silvio E. Inzucchi, Audrey Koitka‐Weber, Michaela Mattheus, Stefan Hantel, Hans‐Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Per‐Henrik Groop

I whakaputaina 2018

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOM... mā Bettina J. Kraus, Matthew R. Weir, George L. Bakris, Michaela Mattheus, David Z.I. Cherney, Naveed Sattar, Hiddo J.L. Heerspink, Ivana Ritter, Maximilian von Eynatten, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Audrey Koitka‐Weber

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp>‐<scp>T2D</scp> trial mā Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, Berthold Hocher, Keizo Kanasaki, Masakazu Haneda, Guntram Schernthaner, Kumar Sharma, Robert C. Stanton, Robert D. Toto, Jessica Cescutti, Maud Gordat, Thomas Meinicke, Audrey Koitka‐Weber, Sandra Thiemann, Maximilian von Eynatten

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

International consensus definitions of clinical trial outcomes for kidney failure: 2020 mā Adeera Levin, Rajiv Agarwal, William G. Herrington, Hiddo J.L. Heerspink, Johannes F.E. Mann, Shahnaz Shahinfar, Katherine R. Tuttle, Jo-Ann Donner, Vivekanand Jha, Masaomi Nangaku, Dick de Zeeuw, Meg Jardine, Kenneth W. Mahaffey, Aliza M. Thompson, Mary Beaucage, Kate Chong, Glenda V. Roberts, Duane Sunwold, Hans Vorster, Madeleine Warren, Sandrine Damster, Charu Malik, Vlado Perkovic, Shuchi Anand, Nicholas B. Argent, Elena Babak, Debasish Banerjee, Jonathan Barratt, Aminu K. Bello, Angelito A. Bernardo, Jaime D. Blais, William Canovatchel, Fergus Caskey, Josef Coresh, Ian H. de Boer, Kai‐Uwe Eckardt, Rhys Evans, Harold I. Feldman, Agnes B. Fogo, Hrefna Guðmundsdóttir, Takayuki Hamano, David C.H. Harris, Sibylle J. Hauske, Richard Haynes, Charles A. Herzog, Thomas F. Hiemstra, Thomas Idorn, Lesley A. Inker, Julie H. Ishida, David W. Johnson, Charlotte Jones-Burton, Amer Joseph, Audrey Koitka‐Weber, Matthias Kretzler, Robert Lawatscheck, Adrian Liew, Louise Moist, Saraladevi Naicker, Reiko Nakashima, Uptal D. Patel, Roberto Pecoits–Filho, Jennifer B. Rose, Noah L. Rosenberg, Marvin Sinsakul, William E. Smoyer, Laura Solá, Amy R. Sood, Bénédicte Stengel, Maarten W. Taal, Mototsugu TANAKA, Marcello Tonelli, Allison Tong, Robert Toto, Michele Trask, Ifeoma Ulasi, Christoph Wanner, David C. Wheeler, Benjamin Ole Wolthers, Harold M. Wright, Yoshihisa Yamada, Elena Zakharova

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: